Loading clinical trials...

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | Clinical Trials | Clareo Health

TERMINATEDPhase 2NCT05918978

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.

Lead sponsor: argenx•9 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusTERMINATED

PhasePHASE2

Enrollment33

Start dateJun 2023

Last updatedOct 23, 2025

Locations shown

UC Sand Diego Sulpizio Cardiovascular Center

La Jolla, California

Standford Movement Disorder Center

Palo Alto, California

North Shore University HealthSystem

Glenview, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 23, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions